12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

AstraZeneca, Merck deal

AstraZeneca and Merck amended the terms of a 2010 option for AstraZeneca to acquire Merck's U.S. interest in AstraZeneca's gastrointestinal drugs Prilosec omeprazole and Nexium esomeprazole. The proton pump inhibitors (PPIs) are part of the companies' JV, AstraZeneca L.P., which markets AstraZeneca's drugs in the...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >